Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling

Drug Metabolism and Disposition

Volumn 35, Issue 1, 2007, Pages 150-167

  Zhang, Donglu ^a   Wang, Lifei ^a   Raghavan, Nirmala ^a   Zhang, Haiying ^a   Li, Wenying ^a   Cheng, Peter T ^a   Yao, Ming ^a   Zhang, Litao ^a   Zhu, Mingshe ^a   Bonacorsi, Samuel ^a   Yeola, Suresh ^a   Mitroka, James ^a   Hariharan, Narayanan ^a   Hosagrahara, Vinayak ^a   Chandrasena, Gamini ^a   Wen, Chyi Shyu ^a   Humphreys, W Griffith ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXY MURAGLITAZAR; 12 HYDROXY O DEMETHYL MURAGLITAZAR; 12,17 DIHYDROXY MURAGLITAZAR; 17 HYDROXY MURAGLITAZAR; 17 HYDROXY O DEMETHYL MURAGLITAZAR; 5 METHYL 2 PHENYLOXAZOYL 4 ACETIC ACID; 8 HYDROXY MURAGLITAZAR; 8 HYDROXY O DEMETHYL MURAGLITAZAR; 8,12 DIHYDROXY MURAGLITAZAR; 9 HYDROXY MURAGLITAZAR; 9 HYDROXY O DEMETHYL MURAGLITAZAR; 9,12 DIHYDROXY MURAGLITAZAR; DI OXYGENATED MURAGLITAZAR; DRUG METABOLITE; HYDROXY MURAGLITAZAR GLUCURONIDE; HYDROXY O DEMETHYL MURAGLITAZAR GLUCURONIDE; MURAGLITAZAR; MURAGLITAZAR 12 CARBOXYLIC ACID; MURAGLITAZAR GLUCURONIDE; O DEALKYL MURAGLITAZAR; O DEALKYL O DEMETHYL MURAGLITAZAR; O DEMETHYL MURAGLITAZAR; O DEMETHYL MURAGLITAZAR GLUCURONIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION DETECTION; RAT; SINGLE DRUG DOSE; SPECIES COMPARISON; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION;

ANIMALS; BILE; DOGS; FECES; GLYCINE; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED STRAINS; OXAZOLES; PPAR ALPHA; PPAR GAMMA; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; CANIS FAMILIARIS;

EID: 33845924787     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012450     Document Type: Article

References (18)

1. Balfour JA and Plosker GL (1999) Rosiglitazone. Drugs 57:921-930.
2. Balfour JA, McTavish D, and Heel RC (1990) Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 40:260-290.
3. Berry MN and Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells. J Cell Biol 43:506-520.
4. Cheng-Lai A and Levine A (2000) Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis 2:326-333.
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1993-1996.
6. Despres JP (2001) Increasing high-density lipoprotein cholesterol: an update on fenofibrate. Am J Cardiol 88 (12A):30N-36N.
7. Devasthale PV, Chen S, Jeon Y, Qu F, Shao C, Wang W, Zhang H, Cap M, Farrelly D, Golla R, et al. (2005) Design and synthesis of N-[(4- methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy] phenyl]methyl] glycine, muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities. J Med Chem 48:2248-2250.
8. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York.
9. Gillies PS and Dunn CJ (2000) Pioglitazone. Drugs 60:333-343.
10. Goldstein BJ (2000) Rosiglitazone. Int J Clin Pract 54:333-337.
11. Harrity T, Farrelly D, Tienman A, Chu C, Kunselman L, Gu L, Cap M, Wu F, Shao C, Wang W, et al. (2006) Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes 55:240-248.
12. Kendall DM, Rubin CJ, Mohideen P, Ledeine LM, Beller R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan GG, et al. (2006) Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual ([alpha]/[gamma]) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29:1016-1023.
13. W, Zhang D, Wang L, Zhang H, Cheng PT, Zhang D, Everett DW, and Humphreys WG (2006) Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites. Drug Metab Dispos 34:807-820.
14. Mudaliar S and Henry RR (2001) New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239-257.
15. Packard KA, Backes JM, Lenz TL, Wurdeman RL, Destache C, and Hilleman DE (2002) Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Pharmacotherapy 22:1527-1532.
16. 14C]muraglitazar in humans: different metabolic profiles in subjects with or without bile collection. Drug Metab Dispos 34:427-439.
17. Zhang D, Zhang H, Aranibar N, Hanson R, Cheng PTW, Huang Y, Bonacorsi S, Swaminathan A, Everett DW, and Humphreys WG (2006) Structure elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards. Drug Metab Dispos 34:267-280.
18. Zhang HY, Zhang DL, and Ray K (2003) A software filter to remove interference ions from drugs metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J Mass Spectrom 38:1110-1112.